Panacea Biotec Ltd.

BSE: PANACEABIO531349ISIN INE922B01023

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹344.80+10.90 (+3.26%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹647.50
52W low: ₹293.10
Off 52W high: -46.75%
1M return: -1.30%
3M return: -17.89%
6M return: -13.53%
1Y return: -20.24%
20D avg volume: 3,553
50 DMA: ₹363.67
200 DMA: ₹398.75

Key ratios Consolidated

Market cap: ₹2,112 Cr
Current price: ₹344.80
52W high / low: ₹647.50 / ₹293.10
Face value: ₹1.00
P/E: -236.76
P/B: 2.53
EPS (TTM): ₹-1.46
Book value / share: ₹136.19
ROE: —
ROCE: -0.10%
Operating margin: —
Net margin: —
Debt / equity: 0.03
Net debt: ₹-33.65 Cr
Interest cover: -0.22
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 43.7 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	199.57	166.75	165.19	141.13	166.70	132.53	163.49	147.35	115.72	136.46	150.50	143.02
	4.24	2.55	2.28	6.40	5.67	8.59	3.62	4.65	3.80	10.81	5.68	3.23
	203.81	169.30	167.47	147.53	172.37	141.12	167.11	152.00	119.52	147.27	156.18	146.25
	202.98	173.26	163.75	169.40	177.13	168.87	165.50	150.01	139.31	152.13	160.61	156.80
	74.17	80.78	90.17	46.58	72.71	83.32	48.74	41.77	40.24	45.53	47.83	59.78
	0.77	2.67	2.38	1.91	2.01	7.45	0.15	—	—	0.49	1.09	—
	44.16	46.82	40.53	47.71	45.72	49.13	42.98	43.44	37.50	38.43	37.65	37.52
	1.18	1.20	1.85	2.14	0.86	1.04	0.99	0.98	0.87	0.82	0.85	0.91
	7.90	7.88	8.45	8.34	8.39	8.42	8.98	8.68	8.73	8.81	9.11	9.31
	48.03	40.97	44.99	52.27	44.94	58.20	50.00	53.72	50.49	54.32	45.68	50.87
	0.83	-3.96	3.72	-21.87	-4.76	-27.75	1.61	1.99	-19.79	-4.86	-4.43	-10.55
	2.74	2.71	2.77	2.70	11.32	27.71	2.77	2.77	2.74	2.74	2.78	2.77
	3.57	-1.25	6.49	-19.17	6.56	-0.04	4.38	4.76	-17.05	-2.12	-1.65	-7.78
	1.37	-0.25	2.60	-5.16	2.60	1.95	0.06	0.05	1.17	0.13	0.55	0.51
	2.20	-1.00	3.89	-14.01	3.96	-1.99	4.44	4.71	-15.88	-1.99	-2.20	-8.29
	0.38	0.08	0.65	-2.27	0.66	-0.31	0.74	0.77	-2.59	-0.23	-0.37	-1.35
Key metrics
	12.65	7.83	16.79	-8.69	15.81	9.42	14.35	14.42	-7.45	7.51	8.31	2.44
	6.30%	4.70%	10.20%	-6.20%	9.50%	7.10%	8.80%	9.80%	-6.40%	5.50%	5.50%	1.70%
	1.10%	-0.60%	2.40%	-9.90%	2.40%	-1.50%	2.70%	3.20%	-13.70%	-1.50%	-1.50%	-5.80%
	—	0.00%	—	-1.90%	—	0.10%	—	—	—	—	—	—
	19.70%	25.80%	1.00%	-4.20%	44.10%	-2.90%	8.60%	3.00%	—	—	—	—
	-44.40%	49.70%	-12.40%	-397.50%	124.90%	0.00%	301.80%	156.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	672.64	639.77	559.09	559.17	459.95	661.23
	15.47	16.90	20.66	25.80	51.66	10.97
	688.11	656.67	579.75	584.97	511.61	672.20
	709.39	683.54	623.69	619.52	601.47	899.59
	291.70	290.24	214.07	210.46	211.03	281.25
	7.73	8.97	7.60	1.80	7.26	29.92
	179.22	180.78	173.05	149.57	126.48	182.94
	6.37	6.05	3.88	3.58	4.44	180.84
	32.57	33.06	34.81	36.71	39.12	43.66
	186.26	183.17	212.41	199.54	—	229.95
	-21.28	-26.87	-43.94	-34.55	-89.86	-227.39
	10.92	19.50	35.99	36.03	102.66	1,676
	-10.36	-7.37	-7.95	1.48	12.80	1,449
	-1.44	-0.21	0.77	2.98	46.55	370.91
	-8.92	-7.16	-8.72	-1.50	-33.75	1,078
	-1.16	-0.88	-1.37	-0.19	-5.51	175.98
Key metrics
	28.58	31.74	30.74	41.77	56.36	1,673
	4.25%	5.00%	5.50%	7.50%	12.30%	253.10%
	-1.33%	-1.10%	-1.60%	-0.30%	-7.30%	163.00%
	—	-0.10%	-0.40%	—	—	—
	10.26%	14.40%	0.00%	21.60%	-30.40%	—
	-180.22%	17.90%	-481.30%	95.60%	-103.10%	—
	—	-37.41	-77.68	—	—	—
	—	-2.33	3.14	—	—	—
	—	0.03	0.03	—	—	—
	—	-33.65	-59.92	—	—	—
	—	43.7	39.5	—	—	—
Balance sheet
	—	1,262	1,290	—	—	—
	—	513.04	545.18	—	—	—
	—	57.31	82.13	—	—	—
	—	73.52	72.56	—	—	—
	—	192.79	213.67	—	—	—
	—	110.13	77.26	—	—	—
	—	553.27	543.39	—	—	—
	—	189.60	225.76	—	—	—
	—	348.68	366.99	—	—	—
	—	23.66	22.21	—	—	—
	—	0.00	0.00	—	—	—
	—	23.66	22.21	—	—	—
	—	828.88	830.62	—	—	—
Cash flow
	—	16.68	-27.37	—	—	—
	—	-40.49	64.98	—	—	—
	—	-1.05	-2.66	—	—	—
	—	54.09	50.31	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	134.71	111.12	99.31	90.81	112.25	67.90	108.43	76.64	56.88	80.37	95.23	94.59
	6.06	5.60	3.84	3.61	4.95	6.09	3.32	3.41	3.80	16.39	3.05	2.13
	140.77	116.72	103.15	94.42	117.20	73.99	111.75	80.05	60.68	96.76	98.28	96.72
	138.77	121.33	112.62	115.35	126.04	96.02	102.10	78.75	75.66	98.11	97.21	93.52
	53.79	58.79	72.88	26.88	60.94	59.37	28.16	22.04	14.44	26.09	23.56	37.09
	0.20	0.01	2.08	0.78	1.14	1.75	—	—	—	—	—	—
	22.83	22.76	25.16	27.04	25.37	27.26	23.78	24.45	21.53	23.29	20.84	22.29
	6.89	6.33	7.04	5.93	6.00	4.64	3.85	3.76	3.21	3.36	3.41	3.55
	4.47	4.18	4.89	4.91	4.77	4.91	5.21	5.09	5.08	5.14	5.21	5.34
	26.58	32.25	27.80	32.07	27.76	32.19	30.95	27.74	26.18	39.29	23.89	26.20
	2.00	-4.61	-9.47	-20.93	-8.84	-22.03	9.65	1.30	-14.98	-1.35	1.07	3.20
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	2.00	-4.61	-9.47	-20.93	-8.84	-22.03	9.65	1.30	-14.98	-1.35	1.07	3.20
	0.61	-4.43	2.11	5.29	-2.14	-9.64	—	0.01	1.20	0.02	0.64	—
	1.39	-0.18	-7.36	-15.64	-6.70	-12.39	9.65	1.29	-13.78	-1.37	0.43	3.20
	0.23	-0.03	-1.20	-2.55	-1.09	-2.02	1.58	0.21	-2.25	-0.22	0.07	0.52
Key metrics
	13.36	5.90	2.46	-10.09	1.93	-12.48	18.71	10.15	-6.69	7.15	9.69	12.09
	9.90%	5.30%	2.50%	-11.10%	1.70%	-18.40%	17.30%	13.20%	-11.80%	8.90%	10.20%	12.80%
	1.00%	-0.20%	-7.40%	-17.20%	-6.00%	-18.20%	8.90%	1.70%	-24.20%	-1.70%	0.50%	3.40%
	—	0.30%	—	-3.00%	—	-3.40%	—	—	—	—	—	—
	20.00%	63.70%	-8.40%	18.50%	97.30%	-15.50%	13.90%	-19.00%	—	—	—	—
	120.70%	98.50%	-176.30%	-1,312.40%	51.40%	-804.40%	2,144.20%	-59.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	435.95	413.49	309.85	359.60	257.07	235.50
	19.11	18.00	16.62	24.91	34.43	12.57
	455.06	431.49	326.47	384.51	291.50	248.07
	488.07	475.34	352.53	380.30	354.25	341.65
	212.34	219.49	124.01	123.90	131.16	172.40
	3.07	4.01	1.75	—	0.75	0.64
	97.79	100.33	97.02	86.53	71.03	72.50
	26.19	25.30	15.46	13.78	10.06	7.04
	18.45	18.75	20.29	21.09	24.50	26.43
	118.70	119.88	117.06	117.21	—	—
	-33.01	-43.85	-26.06	4.21	-62.75	-93.58
	0.00	0.00	0.00	—	—	—
	-33.01	-43.85	-26.06	4.21	-62.75	-93.58
	3.58	13.97	10.83	0.66	24.79	—
	-21.79	-29.88	-15.23	3.55	-87.54	-93.58
	-3.55	-4.88	-2.49	0.58	-14.29	-15.28
Key metrics
	11.63	0.20	9.69	39.08	-28.19	-60.11
	2.67%	0.00%	3.10%	10.90%	-11.00%	-25.50%
	-5.00%	-7.20%	-4.90%	1.00%	-34.10%	-39.70%
	—	-3.30%	-2.00%	—	—	—
	19.37%	33.40%	-13.80%	39.90%	9.20%	—
	—	-96.20%	-529.00%	104.10%	6.50%	—
	—	-73.88	-49.03	—	—	—
	—	1.34	-0.26	—	—	—
	—	0.93	0.73	—	—	—
	—	262.71	189.95	—	—	—
	—	20.8	9.6	—	—	—
Balance sheet
	—	852.42	869.47	—	—	—
	—	284.49	293.73	—	—	—
	—	2.41	38.50	—	—	—
	—	30.68	20.85	—	—	—
	—	126.34	152.10	—	—	—
	—	—	40.45	—	—	—
	—	347.39	347.50	—	—	—
	—	133.44	164.83	—	—	—
	—	285.19	351.41	—	—	—
	—	265.12	228.45	—	—	—
	—	19.18	67.94	—	—	—
	—	245.94	160.51	—	—	—
	—	285.24	313.97	—	—	—
Cash flow
	—	-40.15	3.94	—	—	—
	—	-18.53	-60.60	—	—	—
	—	22.54	90.07	—	—	—
	—	33.73	52.97	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +17.17%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +19.37%
Profit YoY (TTM): -167.36%

Consolidated

Sales CAGR 3Y: +11.63%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +10.26%
Profit YoY (TTM): -180.22%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 72.48%

Quarter	September 2026	June 2026
Promoter %	72.48%	72.48%

Holder	Type	Holding	Previous	Change
Dr. Rajesh Jain	Promoter	49.01%	49.01%	0.00%
Mr. Sandeep Jain	Promoter	15.27%	15.27%	0.00%
Mrs. Nirmala Jain	Promoter Group	4.10%	4.10%	0.00%
First Lucre Partnership Co.	Promoter Group	3.68%	3.68%	0.00%
Massachusetts Institute of Technology	Public	1.81%	1.71%	+0.10%
Viral Amal Parikh	Public	1.47%	1.47%	0.00%
Rajesh Jain (HUF)** (Karta : Rajesh Jain)	Promoter Group	0.33%	0.33%	0.00%
Second Lucre Partnership Co.	Promoter Group	0.09%	0.09%	0.00%
Mrs. Meena Jain	Promoter Group	0.00%	0.00%	0.00%
Mrs. Priyanka Jain	Promoter Group	0.00%	0.00%	0.00%
Mr. Ankesh Jain	Promoter Group	0.00%	0.00%	0.00%
Mr. Harshet Jain	Promoter Group	0.00%	0.00%	0.00%
Sandeep Jain (HUF) (Karta : Sandeep Jain)	Promoter Group	0.00%	0.00%	0.00%
Mr. Ashish Jain	Promoter Group	0.00%	0.00%	0.00%
Mrs. Pamilla Jain	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Panacea Biotec Ltd.	2,112	344.80	-236.76	-0.10%	+10.26% TTM	-180.22% TTM	-20.24%

Filings & corporate actions

Recent announcements

Please find attached newspaper copies regarding notice intimating the investors about the opening of special window for transfer and dematerialisation of physical shares9 Oct 2026 · Company Update / Newspaper Publication
Please find attached certificate dated October 01, 2026 issued by Skyline Financial Services Pvt. Ltd. ("RTA") confirming compliance under Regulation 74(5) of the SEBI (Depositories and ....7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find attached details of shares dematerialised during September 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 20187 Oct 2026 · Company Update / General
Please find attached voting results of 42nd Annual General Meeting of the Company held on 29.09.2026 along with Scrutinizer''s Report1 Oct 2026 · AGM/EGM / AGM
Please find attached voting results of 42nd Annual General Meeting held on 29.09.2026 along with Scrutinizer''s Report1 Oct 2026 · AGM/EGM / AGM
Please find attached proceedings of the 42nd Annual General meeting of the Company held on Tuesday, September 29, 2026 at 11:30 A.M. through Video Conferencing.29 Sep 2026 · AGM/EGM / AGM
We would like to inform you that the Company has received 2 Demand Orders dated 28.09.2026, from the Office of the Assistant Commissioner of Income Tax, Delhi imposing penalty on account ....29 Sep 2026 · Company Update / General
The Company has received four Demand Orders from the Office of the Assistant Commissioner of Income Tax, Delhi under Section 156 of the Income Tax Act, 1961 ("Act") imposing penalty on ....26 Sep 2026 · Company Update / General
The trading window of the Company shall remain closed for all the Designated Persons (including their immediate relatives) of the Company from October 01, 2026 till completion of 48 hours ....26 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please note that reminder letters dated 15.09.2026, is being sent to the shareholders holding shares in physical mode, requesting them to furnish PAN and KYC details for updation, to the ....15 Sep 2026 · Company Update / General
Please find enclosed copies of newspaper advertisement regarding Notice of 42nd AGM, Cut-off date and Remote e-Voting information, published on September 08, 2026.8 Sep 2026 · Company Update / Newspaper Publication
Please find attached intimation regarding Book Closure for the purpose of Annual General Meeting.7 Sep 2026 · Corp. Action / Book Closure
Please find attached intimation of letter being sent to shareholders for providing web-link for accessing Annual Report and AGM Notice for FY 2025-267 Sep 2026 · Company Update / General
Please find attached Business Responsibility and Sustainability Report for FY 2025-267 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find attached Annual Report for FY 2025-267 Sep 2026 · Others / Reg. 34 (1) Annual Report
Please find attached Annual Report for Financial Year 2025-26 including Notice of AGM7 Sep 2026 · AGM/EGM / AGM
Please find attached details of shares dematerialised during August 2026. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services Pvt. Ltd. regarding ....7 Sep 2026 · Company Update / General
Please find enclosed newspaper copies of the public notice, requesting shareholders to register their email addresses with the Company in connection with ensuing AGM of the Company.18 Aug 2026 · Company Update / Newspaper Publication
Please find attached of the extract of statement of Unaudited Financial Results for the quarter ended 30.06.2026, published on 14.08.2026.14 Aug 2026 · Company Update / Newspaper Publication
Please find attached Unaudited Financial Results for quarter ended June 30, 2026.13 Aug 2026 · Result / Financial Results
Please find attached Outcome of Board Meeting held on August 13, 2026.13 Aug 2026 · Board Meeting / Outcome of Board Meeting
Please find attached newspaper copies regarding notice intimating the investors about the opening of Special Window for transfer and dematerialisation of physical shares.12 Aug 2026 · Company Update / Newspaper Publication
Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....8 Aug 2026 · Board Meeting / Board Meeting
Please find attached details of shares dematerialised during July 2026.5 Aug 2026 · Company Update / General
We are delighted to inform you that the Company has received Letter of Award for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF in 10 and 20 dose presentation worth ~US$8.205 million ....5 Aug 2026 · Company Update / Award of Order / Receipt of Order
The Company''s wholly owned subsidiary, Panacea Biotec Pharma Ltd. has received a Show Cause Notice (SCN) dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services ....24 Jul 2026 · Company Update / General
We would like to inform you that the Company has on July 16, 2026, filed appeal before the Hon''ble High Court of Punjab and Haryana, Chandigarh, against the remaining 4th award. The ....16 Jul 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....13 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
Please find attached disclosure which is self explanatory7 Jul 2026 · Company Update / General
Please find attached certificate dated July 01, 2026, issued by Skyline Financial Services Pvt. Ltd. , RTA under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, ....7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We would like to inform that no share has been dematerialised during June 2026. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services Pvt. Ltd. ....7 Jul 2026 · Company Update / General
We would like to inform you that the trading window of the Company shall remain closed from July 01, 2026 till completion of 48 hours from the announcement of the Unaudited financial results ....26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Rajesh Jain17 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
Please find attached newspaper copies regarding notice intimating the investors about the opening of a special window for transfer and dematerialisation of physical shares.16 Jun 2026 · Company Update / Newspaper Publication
Panacea Biotec is pleased to inform the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll in sub-Saharan Africa (sSA) and to facilitate ....8 Jun 2026 · Company Update / Press Release / Media Release
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....5 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011
Please find attached details of shares dematerialised during May 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 20185 Jun 2026 · Company Update / General
Please find attached copies of newspaper publication of Audited Financial Results for the quarter and financial year ended March 31, 2026.1 Jun 2026 · Company Update / Newspaper Publication
Please find attached results31 May 2026 · Result / Financial Results
We would like to inform you that the Board of Directors has at its meeting held today i.e. 30.05.2026 approved the appointment of Mr. Rajinder Singh Manku as an additional director in the ....30 May 2026 · Company Update / Change in Directorate

Board meetings

13 Aug 2026 Board Meeting - Financial Results